chartexchange

Grace Therapeutics Announces Second Quarter 2027 Financial Results, Provides Business Update

GlobeNewswire Inc. | Nov 12, 2026 8:00 AM EST

PRINCETON, N.J., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage biopharma company advancing GTx-104, a novel, injectable formulation of nimodipine that has completed a Phase 3 clinical trial and is being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended September 30, 2026.

Read original article